In his articles, Myron S. Czuczman combines various disciplines, including Lymphoma and Diffuse large B-cell lymphoma. Myron S. Czuczman applies his multidisciplinary studies on Diffuse large B-cell lymphoma and Lymphoma in his research. His study brings together the fields of Pharmacokinetics and Internal medicine. His research on Pharmacokinetics often connects related areas such as Internal medicine. Rituximab and International Prognostic Index are two areas of study in which Myron S. Czuczman engages in interdisciplinary research. He performs multidisciplinary study in the fields of International Prognostic Index and Rituximab via his papers. Myron S. Czuczman connects Chemotherapy with Phases of clinical research in his research. His Phases of clinical research study frequently draws connections to other fields, such as Surgery. His Surgery study frequently draws parallels with other fields, such as Neutropenia.
As part of his Cyclophosphamide, Neutropenia and Phases of clinical research and Chemotherapy studies, Myron S. Czuczman is studying Chemotherapy. Myron S. Czuczman incorporates Cyclophosphamide and Rituximab in his studies. Rituximab and Follicular lymphoma are two areas of study in which Myron S. Czuczman engages in interdisciplinary work. Borrowing concepts from Antibody, he weaves in ideas under Follicular lymphoma. He conducted interdisciplinary study in his works that combined Antibody and Radioimmunotherapy. He regularly ties together related areas like Adverse effect in his Internal medicine studies. While working on this project, he studies both Lymphoma and Diffuse large B-cell lymphoma. Myron S. Czuczman brings together Diffuse large B-cell lymphoma and Lymphoma to produce work in his papers. In his research, he performs multidisciplinary study on Oncology and Gastroenterology.
In his research, Myron S. Czuczman undertakes multidisciplinary study on Lymphoma and Follicular lymphoma. His work blends Follicular lymphoma and CD20 studies together. He merges many fields, such as CD20 and Rituximab, in his writings. He combines Rituximab and International Prognostic Index in his research. Myron S. Czuczman combines International Prognostic Index and Diffuse large B-cell lymphoma in his studies. He merges many fields, such as Diffuse large B-cell lymphoma and Multiple myeloma, in his writings. He merges many fields, such as Multiple myeloma and Lymphoma, in his writings. His research on Internal medicine frequently links to adjacent areas such as Confidence interval. He conducts interdisciplinary study in the fields of Confidence interval and Hazard ratio through his research.
His Internal medicine study frequently involves adjacent topics like Neutropenia. Myron S. Czuczman combines Neutropenia and Febrile neutropenia in his research. His research on Febrile neutropenia often connects related areas such as Surgery. His research brings together the fields of Data monitoring committee and Surgery. Myron S. Czuczman integrates Data monitoring committee with Clinical trial in his study. He applies his multidisciplinary studies on Clinical trial and Randomized controlled trial in his research. His Randomized controlled trial study frequently draws connections to other fields, such as Internal medicine. Myron S. Czuczman integrates Chemotherapy with Cancer research in his study. His study deals with a combination of Cancer research and Chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
P McLaughlin;A J Grillo-López;B K Link;R Levy.
Journal of Clinical Oncology (1998)
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
Thomas E. Witzig;Leo I. Gordon;Fernando Cabanillas;Myron S. Czuczman.
Journal of Clinical Oncology (2002)
Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
Myron S. Czuczman;A. J. Grillo-López;C. A. White;M. Saleh.
Journal of Clinical Oncology (1999)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H Wilson;Owen A O'Connor;Myron S Czuczman;Ann S LaCasce.
Lancet Oncology (2010)
Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma
Thomas E. Witzig;Ian W. Flinn;Leo I. Gordon;Christos Emmanouilides.
Journal of Clinical Oncology (2002)
Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment
Thomas A. Davis;Antonio J. Grillo-López;Christine A. White;Peter McLaughlin.
Journal of Clinical Oncology (2000)
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou;Laurie H. Sehn;Alfred W. Rademaker;Leo I. Gordon.
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
Kieron Dunleavy;Stefania Pittaluga;Myron S. Czuczman;Sandeep S. Dave.
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
N. L. Berinstein;A. J. Grillo-Lopez;C. A. White;I. Bence-Bruckler.
Annals of Oncology (1998)
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
L. D. Piro;C. A. White;A. J. Grillo-López;N. Janakiraman.
Annals of Oncology (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: